Literature DB >> 23011159

Different expression of EZH2, BMI1 and Ki67 in low and high grade neuroendocrine tumors of the lung.

Anna-Louise Reinert Ørsum Bondgaard1, Thomas Tuxen Poulsen, Hans Skovgaard Poulsen, Birgit Guldhammer Skov.   

Abstract

BACKGROUND: Enhancer of Zeste Homolog 2 (EZH2) and B lymphoma Mo-MLV Insertion region 1 polycomb ring finger (BMI1) are involved in malignant transformation of many human carcinomas. Still, in neuroendocrine tumors of the lung (NELT) their expression pattern is largely unknown. This study evaluated their expression in 96 NELT and correlated it to clinical features including survival.
MATERIALS AND METHODS: Paraffin embedded material from 50 typical carcinoids (TC), 13 atypical carcinoids (AC), 23 large cell neuroendocrine carcinomas (LCNEC) and 10 small cell lung carcinomas (SCLC) was evaluated by immunohistochemisty.
RESULTS: Significantly higher expression of EZH2 was found in high grade NELT (LCNEC + SCLC) versus low grade NELT (TC + AC) (p < 0.0001). High expression of BMI1 was observed in low grade NELT (TC + AC) in contrast to the expression in high grade NELT (LCNEC+SCLC) (p=0.004). In multivariate models, diagnosis was the strongest predictor of survival.
CONCLUSION: The immunohistochemical expression of EZH2 and BMI1 are significantly different in low versus high grade NELT. This difference might be related to NELT tumorigenesis. These markers have no independent prognostic impact in NELT. Whether EZH2 could become target in new treatments strategies against NELT remains to be elucidated.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23011159     DOI: 10.3233/CBM-2012-0269

Source DB:  PubMed          Journal:  Cancer Biomark        ISSN: 1574-0153            Impact factor:   4.388


  6 in total

1.  Enhancer of Zeste Homolog 2 (EZH2) Is a Marker of High-Grade Neuroendocrine Neoplasia in Gastroenteropancreatic and Pulmonary Tract and Predicts Poor Prognosis.

Authors:  Sebastian C B Bremer; Gabi Bittner; Omar Elakad; Helen Dinter; Jochen Gaedcke; Alexander O König; Ahmad Amanzada; Volker Ellenrieder; Alexander Freiherr von Hammerstein-Equord; Philipp Ströbel; Hanibal Bohnenberger
Journal:  Cancers (Basel)       Date:  2022-06-08       Impact factor: 6.575

2.  Genomic pathway analysis reveals that EZH2 and HDAC4 represent mutually exclusive epigenetic pathways across human cancers.

Authors:  Adam L Cohen; Stephen R Piccolo; Luis Cheng; Rafaella Soldi; Bing Han; W Evan Johnson; Andrea H Bild
Journal:  BMC Med Genomics       Date:  2013-09-30       Impact factor: 3.063

3.  Prognostic Value of EZH2 in Non-Small-Cell Lung Cancers: A Meta-Analysis and Bioinformatics Analysis.

Authors:  Kui Fan; Chuan-Long Zhang; Yuan-Fu Qi; Xin Dai; Yoann Birling; Zhao-Feng Tan; Fang Cao
Journal:  Biomed Res Int       Date:  2020-11-09       Impact factor: 3.411

Review 4.  Recent advances and conceptual changes in the classification of neuroendocrine tumors of the thymus.

Authors:  Hanibal Bohnenberger; Philipp Ströbel
Journal:  Virchows Arch       Date:  2021-02-08       Impact factor: 4.064

Review 5.  Management of Large Cell Neuroendocrine Carcinoma.

Authors:  Virginia Corbett; Susanne Arnold; Lowell Anthony; Aman Chauhan
Journal:  Front Oncol       Date:  2021-08-27       Impact factor: 6.244

6.  miR-21 modulates the effect of EZH2 on the biological behavior of human lung cancer stem cells in vitro.

Authors:  Hui Xia; Wen Zhang; Baoshi Zhang; Yingnan Zhao; Yunlong Zhao; Shaojun Li; Yang Liu
Journal:  Oncotarget       Date:  2017-08-07
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.